Skip to Content
Merck
CN
All Photos(4)

Documents

Safety Information

SAB1400064

Sigma-Aldrich

Anti-CYP3A4 antibody produced in mouse

IgG fraction of antiserum, buffered aqueous solution

Sign Into View Organizational & Contract Pricing
All Photos(4)
Synonym(s):
Anti-CP33, Anti-CP34, Anti-CYP3A, Anti-CYP3A3, Anti-HLP, Anti-MGC126680, Anti-NF-25, Anti-P450C3, Anti-P450PCN1
MDL number:
MFCD01633033
UNSPSC Code:
12352203
NACRES:
NA.41

biological source

mouse

Quality Level

100

conjugate

unconjugated

antibody form

IgG fraction of antiserum

antibody product type

primary antibodies

clone

polyclonal

form

buffered aqueous solution

species reactivity

human

technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable
western blot: 1 μg/mL

UniProt accession no.

P08684

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... CYP3A4(1576)

General description

Cytochrome P450 3A4 (CYP3A4), the ubiquitous cytochrome P450 (CYP) seen in the adult liver and intestine, belongs to the CYP3A subfamily. The CYP3A4 gene with 13 exons is located on human chromosome 7q22.1.

Immunogen

CYP3A4 (AAI01632.1, 1 a.a. ~ 503 a.a) full-length human protein.

Sequence
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMFDMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISIAEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYSMDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICVFPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSIIFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVVNETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFSKKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLGGLLQPEKPVVLKVESRDGTVSGA

Application

Anti-CYP3A4 antibody produced in mouse has been used in the immunohistochemical analysis (1:100) and immunofluorescence staining (1:200).

Biochem/physiol Actions

Cytochrome P450 3A4 (CYP3A4) plays a key role in the metabolism of several antineoplastic drugs. It aids in the catalysis of a wide range of substrates. CYP3A4 can detoxify bile acids. CYP3A4 gene mutations can disrupt the metabolism of commonly used medications, resulting in harmful blood concentrations of drugs. Such CYP3A4 polymorphisms may also affect the detoxification of bile acid.

Physical form

Solution in phosphate buffered saline, pH 7.4

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

常规特殊物品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Human Pluripotent Stem Cell-Derived Organoids as a Model of Intestinal Xenobiotic Metabolism
Sasaki K, et al.
Stem cell investigation, 1-10 (2021)
Assessing rat liver-derived biomatrix for hepatic tissue engineering with human fetal liver stem cells
Xu B, et al.
advanced techniques in biology & medicine, 1(3), 00012-00012 (2016)
Jiezhong Chen et al.
Annals of translational medicine, 2(1), 7-7 (2014-10-22)
CYP3A4 is a major cytochrome P450. It catalyses a broad range of substrates including xenobiotics such as clinically used drugs and endogenous compounds bile acids. Its function to detoxify bile acids could be used for treating cholestasis, which is a
Functional assessment of the effects of CYP3A4 variants on acalabrutinib metabolism in vitro
Han M, et al.
Chemico-Biological Interactions, 109559-109559 (2021)
Applications of genotyping and phenotyping for clinically-relevant polymorphisms of drug metabolizing enzymes and drug transporters
Lazar A, et al.
Handbook of Analytical Separations , 5, 321-354 (2004)

Articles

Phase I Drug Metabolism

Phase I biotransformation reactions increase drug compound polarity, mainly occurring in hepatic circulation.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service